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40Several approaches have been developed for gene therapy in RPE65-related Leber
congenital amaurosis. To date, strategies that have reached the clinical stages rely
on adeno-associated viral vectors and two of them documented limited long-term
effect. We have developed a lentiviral-based strategy of RPE65 gene transfer that
efficiently restored protein expression and cone function in RPE65-deficient mice.
In this study, we evaluated the ocular and systemic tolerances of this lentiviral-
based therapy (LV-RPE65) on healthy nonhuman primates (NHPs), without adjuvant
systemic anti-inflammatory prophylaxis. For the first time, we describe the early
kinetics of retinal detachment at 2, 4, and 7 days after subretinal injection using
multimodal imaging in 5 NHPs. We revealed prolonged reattachment times in
LV-RPE65–injected eyes compared to vehicle-injected eyes. Low- (n 5 2) and
high-dose (n 5 2) LV-RPE65–injected eyes presented a reduction of the outer
nuclear and photoreceptor outer segment layer thickness in the macula, that was
more pronounced than in vehicle-injected eyes (n 5 4). All LV-RPE65–injected
eyes showed an initial perivascular reaction that resolved spontaneously within
14 days. Despite foveal structural changes, full-field electroretinography indicated
that the overall retinal function was preserved over time and immunohistochemistry
identified no difference in glial, microglial, or leucocyte ocular activation betweenion and Regeneration, Department
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Volume 188 Matet et al 41low-dose, high-dose, and vehicle-injected eyes. Moreover, LV-RPE65–injected
animals did not show signs of vector shedding or extraocular targeting, confirming
the safe ocular restriction of the vector. Our results evidence a limited ocular toler-
ance to LV-RPE65 after subretinal injection without adjuvant anti-inflammatory pro-
phylaxis, with complications linked to this route of administration necessitating to
block this transient inflammatory event. (Translational Research 2017;188:40–57)Abbreviations: NHP ¼ nonhuman primates; LE ¼ left eye; RE ¼ right eye; IOP ¼ intraocular pres-
sure; EZ ¼ ellipsoid zone; ONL ¼ outer nuclear layer; ERG ¼ electroretinogramENTARY
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contribute to elucidate several limitations of the
subretinal route approach. These observations
contribute to optimizing the translational process
of retinal gene therapy, from both the surgical
and the gene transfer perspectives, and highlight
the necessity to improve lentiviral vector tolerance
by antiinflammatory pretreatment.INTRODUCTION
Retinal dystrophies, especially those with childhood
onset, are a lifetime burden for affected individuals,
with no available treatments. Recently, retinal gene
therapy based on subtypes of adeno-associated virus
(AAV)1-6 or lentivirus-derived vectors7-10 has made
tremendous advances to correct several monogenic
diseases in rodent and large animal models providing
the ground to design first clinical trials and translate
this technology in humans.11 The first gene augmenta-
tion strategy in an inherited retinal disorder was devel-
oped clinically for patients with Leber congenital
amaurosis due to RPE65 deficiency.12 RPE65 is a
retinal pigment epithelium (RPE)–expressed enzyme
with isomerase activity, which plays a key role in the
visual cycle by recycling chromophores necessary
for the phototransduction.13-15 Three main clinical
trials initiated in the US16,17 and UK18 based on the
AAV2/2-vector approach demonstrated a limited
safety with partial, and in 2 trials transitory, visual
function restoration. In one trial, inflammation
induced by AAV2/2 vector at the highest dose required
redesigning of the vector using an AAV5 capsid.19 In
addition, ongoing trials are conducted in Israel
with the AAV2/2 vector developed by the group of
Hauswirth,20 and in France with the AAV2/4 vector.21
The major visual improvements were attested using
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increased retinal sensitivity in the treated area of
certain patients. Functional magnetic resonance
imaging of the visual cortex showed contrast
discrimination enhancement, for a subset of
patients24 and mobility testing demonstrated the abil-
ity to better navigate after treatment in certain
patients.22,25 Differences in the effect of gene
therapy between these different trials, or between
treated patients, results probably from multiple
factors, including the timing of intervention during
disease course, surgical delivery techniques
(administered volume, flow rate, procedure), vector
designs, and patient genetic backgrounds. Moreover,
subjective parameters used to reveal the effect of
gene therapy such as visual acuity or retinal
sensitivity testing might be biased, despite efficient
viral transduction, because of cortical amblyopia
following long-standing visual loss in early childhood.
The major hurdle experienced in these trials was that
subretinal injection under the macula induced, in several
patients, retinal thinning and/or foveal morphologic
changes, which were not foreseeable and may have
contributed to the lack of central vision restoration.22,26
Because inclusion of control subjects receiving the buffer
solution subretinally was not planned in these studies for
obvious ethical reasons, it is not clear whether the
surgery by itself is deleterious or whether the vector
contributes to these unexpected retinal alterations.
In addition, despite improvements in visual sensitivity,
the degenerative rate of the treated eye remained similar
to the nontreated eye,22,23 indicating either an
unstoppable disease progression, inappropriate
treatment delivery (timing of treatment, surgical
techniques), or an insufficient vector efficacy.19 The
available amount of chromophore is determinant for
photoreceptor function and survival, and consequently
RPE65 expression levels are correlated to retinal function
and to the rate of retinal degeneration in animal models.
For instance, in the Rpe65R91W/R91Wmouse model, where
the amount of RPE65 is decreased by around 90%, elec-
troretinography showed a 3-log reduction in retinal sensi-
tivity at 1-month of age, as compared with wild-type
mice, which is correlated to the level of RPE65 protein.27
In human, no electroretinogram (ERG) responses were
observed after RPE65 gene transfer, whereas similar
doses in dogs deficient for the samegene led to clinical re-
sponses, such as recovery of retinal activity and vision-
guided mobility.21,28 To note, dogs injected with
suboptimal doses also showed improvement of visual
behavior without ERG amelioration.22,29 These
discrepancies between clinical observations and animal
studies raised concerns over viral vector efficacy in
humans. Taking into account the data generated byBainbridge et al. (2015), a 200-fold increase in gene
expression could be necessary in humans to reach similar
therapeutic effects as in canine models.19,22
In this context, the development of optimized vec-
tors is a necessary step to improve gene expression af-
ter gene transfer. We previously investigated the
efficacy of lentiviral vectors (LVs) for RPE65 gene
transfer in rodent models, and showed the rescue of
100% of cones in the treated area of Rpe65 knock-
out mice30 and the reactivation of cone cellular func-
tion during the course of degeneration in Rpe65R91W/
R91W mice,31 an effect not reported so far. To further
progress toward the clinical application of LVs for
RPE65 deficiency, we have evaluated a GMP (Good
Manufacturing Practice)–like production of an LV ex-
pressing the hRPE65 gene under the hRPE65 pro-
moter,30 injected subretinally into the eyes of
nonhuman primates (NHPs). No systemic adjuvant
anti-inflammatory prophylaxis was administered, con-
trary to other safety studies performed in large
animals,21,28,32-34 to detect potential side effects not
observed in rodents that may occur when translating
this gene therapy to primates.
The aim of this study was to evaluate the ocular and
systemic safety of this LV following subretinal adminis-
tration, in terms of retinal structure, retinal function, and
systemic biodistribution.METHODS
Animals and study design. This safety study on 5
na€ıve female Macaca fascicularis (3–6 years old),
adhered to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research and
obtained an institutional permission from the French
Ministry of Agriculture after evaluation by the local
ethical committee (2015062915001228vl). All pro-
cedures were performed in an approved user establish-
ment (agreement number 92-032-02), in compliance
with the European directive 2010/63/UE and French
regulations. Animals were socially housed, had
access to standard certified commercial primate food
(Altromin, Genestil, Royaucourt, France) and pro-
cessed municipal tap water, with food supplements
such as fresh fruits. Room temperature was main-
tained at 20C–24C, with 55 6 10% humidity and
12/12 light-dark cycle. Psychological and
environmental enrichment was provided. Animals
were regularly checked for clinical signs or other
changes by caretakers and examined by the
veterinary staff when needed.
To reduce the number of animals used in the study,
and according to existing reports indicating an
absence of systemic inflammatory reaction following
Table I. Description of eyes receiving the LV-RPE65 lentiviral vector or the vehicle (TSSM), in 5 female Macaca
fascicularis
Monkey ID Eye Group Time of sacrifice Comments
1A RE TSSM 30 d after RE/LE injection
LE LV-RPE65 dose 1 Injected same day as RE
1B RE LV-RPE65 dose 1 30 d after RE injection
LE -
2A RE TSSM 90 d after LE injection
LE LV-RPE65 dose 2 Injected 30 d after RE
2B RE TSSM 90 d after LE injection
LE LV-RPE65 dose 2 Injected 30 d after RE (1 accidental intravitreal
dose 1 1 subretinal dose)
C RE TSSM 90 d after RE injection
LE -
Abbreviations: LE, left eye; RE, right eye.
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solution (LV-RPE65) in one eye and the vehicle
(TSSM) in the other eye. The fourth NHP received
LV-RPE65 only in one eye and the fifth NHP received
the vehicle only in one eye, this latter serving as
negative control for the systemic biodistribution study
(Table I). Two NHPs received a dose 1 of LV-RPE65
solution (2.8 3 105 IU in 100 mL; animals 1A and
1B), estimated to yield approximately one infectious
particle per RPE cell in the detached retinal area
and 2 other NHPs received LV-RPE65 at dose
2 5 10 3 dose 1 (2.8 3 106 IU in 100 mL; animals
2A and 2B). After the last clinical evaluation time
point corresponding to the date of scheduled death,
animals were sacrificed by intravenous injection of
sodium pentobarbital and eyes and other organs were
sampled.
Lentiviral vector production. The LV-RPE65 LV
solution used in this study is a GMP-like production of
a vector whose recombinant genome is similar to the
one evaluated previously in RPE65-deficient
mice.30,31,35 Briefly, the LV-RPE65 is an integrative,
third-generation, replication-defective, self-inactivating
human immunodeficiency virus (HIV)-1–derived LV,
with a mutated Woodchuck hepatitis virus
Posttranscriptional Regulatory Element (WPRE)
sequence devoid of promoter activities or open-reading
frames.36 It contains the R0.8 promoter (800 bp of the
human RPE65 promoter)28,37 which drives directly the
expression of the RPE65 cDNA (without introns). For
this study, we used the human RPE65 cDNA, while
the mouse RPE65 cDNA was used previously to
demonstrate vector efficacy in RPE65 mouse
models.30,31,35
The RPE65 LV (LV-RPE65) was produced by
transient transfection of suspended HEK293 T cells
in a serum-free media (customized F17 medium,
Invitrogen, Carlsbad, Calif), in a 10-L glass bioreactor(Biostat B-DCU, Sartorius, G€ottingen, Germany).
Briefly, LV-RPE65 was produced by transient
4-plasmid transfection with polyethylenimine
(PEIpro, Polyplus-transfection, Illkirch-Graffenstaden,
France) as transfection reagent. To enhance viral
production, sodium butyrate was added 24 hours after
transfection at a final concentration of 10 mM. To
remove contaminating DNA a benzonase/Dnase
solution (50 U/mL) was added 24 hours after transfec-
tion in the culture media. The cell supernatant was
harvested 48-hour after transfection and filtered
through 20/3/0.45-mm filters to discard cell debris
and purified by following pre-GMP guidelines. The
downstream purification process included an ion
exchange chromatography, a concentration using a
tangential flow filtration in a hollow fiber with
750-kDa cutoff (GE Healthcare, Little Chalfont, UK)
and a final formulation in TSSM buffer (tromethamine
20 mM, NaCl 100 mM, sucrose 10 mg/mL, and
mannitol 10 mg/mL).
Subretinal administration of LV or vehicle. Surgical
procedures were performed after an overnight fasting
period under general anesthesia with tracheal intubation
and maintenance of spontaneous breathing. Anesthesia
was induced by intramuscular ketamine chlorhydrate
(100 mg/ml; 0.4-0.8 ml) and xylazine (20 mg/ml;
0.1-0.15 ml), followed by continuous intravenous
propofol infusion (10 mg/ml; 1 ml then 3-5 ml/h).
All surgeries were performed by an experienced
vitreoretinal surgeon (FBC) using a 3-port, sutureless
pars plana vitreoretinal surgery system with valved
25-gauge trocars (Constellation, Alcon Laboratories,
Inc, Fort Worth, Tex), after pupil dilation with tropica-
mide 1% and double povidone iodine disinfection of
periocular skin, eyelids, and conjunctiva. The infusion
line was placed inferotemporally, the left superior port
was used for the light fiber and the right superior port
for the injection cannula. A 41-gauge ‘De Juan’
Translational Research
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subretinal injections. To minimize dead volume, it was
connected via a custom low-caliber line to a 100-mL
Hamilton Syringe (Sigma-Aldrich, St. Louis, Mo). Sub-
retinal injections were performed at a site superior to the
macula and adjacent to the superior arcade to obtain a
macular detachment. No prophylactic systemic anti-
inflammatory treatment was administrated before or at
the time of the procedure. After injections, eyes
received a single application of dexamethasone/oxytet-
racycline ointment. In one case of intense intraocular
inflammation during the first postoperative week, anti-
inflammatory treatment by intravenous or intramuscular
methylprednisolone 1 mg/kg was administered daily
during 3 days.
Clinical evaluation and multimodal retinal imaging. At
each clinical evaluation time-point, anesthesia was
performed similarly as for surgical procedures.
Urine (150 mL), venous blood (150 mL), and tears
(20–50 mL) were sampled for viral particle shedding
assays at days 0, 2, 4, 7, 14, and 28 in all animals, and
additionally at day 90 for animals 2A, 2B, and C.
Intraocular pressure (IOP) was measured using the iCare
rebound tonometer (Icare Finland Oy, Vantaa, Finland).
After pupil dilation with tropicamide 1%, the degree of
intraocular inflammation was assessed by a trained
ophthalmologist by grading the density of cells in the
anterior chamber and vitreous in a 1 3 1-mm focused
slit-lamp beam with 25 3 magnification: 0 (no cells),
11 (5–10 cells), 21 (10–25 cells), 31 (25–50 cells),
and 41 (.50 cells).
The fundus was assessed by indirect fundoscopy
and fundus color photograph with the Smartscope
camera (Optomed, Oy, Oulu, Finland). Optical
coherence tomography (OCT), infrared reflectance,
short-wavelength autofluorescence, and blue reflectance
imaging were performed on Spectralis (Heidelberg
Engineering, Heidelberg, Germany). If needed,
fluorescein and indocyanine green angiography were
additionally performed using Spectralis.
Optical coherence tomography analysis. Serial
horizontal and vertical 30-degrees OCT sections
acquired at the level of the fovea were processed using
the automated layer segmentation tool of the Spectralis
software (Heidelberg Eye Explorer, version 1.9.10.0) to
obtain the layer thickness profiles for the total
neurosensory retina (from internal limiting membrane
to RPE), the outer nuclear layer (ONL, from its
interface with the outer plexiform layer to the outer
limiting membrane, OLM), and the photoreceptor outer
segments–RPE complex (POS 1 RPE, from OLM to
RPE). In each scan, the mean thickness corresponding
to the detached area of the retina was extracted and
calculated using a custom algorithm on MATLAB(version 2015b, MathWorks, Natick, Mass). At each
time point, the mean layer thickness was estimated
within the detached area by averaging the thickness
obtained from the horizontal and vertical OCT scans.
An additional segmentation of retinal layers was
performed using the custom-made DiOCTA software
for OCT raw data analysis as described previously,38
over an identical area within the detached retina in all
eyes. This 1-mm-diameter circular area was located
1.1 mm superior and 2.2 mm nasal to the fovea, using
as horizontal reference a straight line from the optic
disc center to the fovea (Supplementary Fig 1). The
distance between the injection site and this area was at
least 3 disc diameters.
Electrophysiology. The ERG recordings were per-
formed in all animals 1 week before the surgical proced-
ures (baseline), 16 days and 30 days after the procedure,
and additionally 90 days after the procedure in animals
2A, 2B, and C. Anesthesia with tracheal intubation and
spontaneous breathing was obtained by intramuscular
ketamine chlorhydrate and intravenous medetomidine
hydrochloride administrations. Animals were prepared
and recorded in a dim light room as previously
described.39,40 A 10.2.55 version Visiosystem (Siem
Bio-Medicale, N^ımes, France) was used to generate the
flash stimuli, as well as to record and analyze the ERG
responses. Binocular full-field ERGs were elicited with
2 photostimulators (source: achromatic LEDs) for
background conditions and flash stimulations
(maximum intensity: 1.9 log cds/m2). First, the cone
system was tested in photopic conditions against a
bright background (25 cd.m22) aimed at desensitizing
the rod system during 10 minutes. Photopic responses
were obtained with 9 decreasing intensities of a series
of 15 white LED bright flashes stimuli (from 1.90 log
cd.s.m22 to 20.80 log cd.s.m22) delivered at 1.3 Hz
(interstimuli interval of 769 ms) to determine the
‘‘Imax’’ intensity corresponding to the maximum b-wave
amplitude (V max) observed at the saturation point of
the luminance curve (maximum cone system
response).41,42 Following determination of the Imax at
each time point, the flicker ERG responses were
obtained with white flash stimuli of Imax intensity
delivered at 30 Hz during at least 15 seconds. Then the
light was switched off and the rod system tested in
scotopic conditions. After 20 minutes of dark
adaptation, scotopic responses were obtained in dark
conditions with an average of 5 dim light flashes
(intensity: 21.1 log cd.s.m22) delivered at 0.1 Hz
temporal frequency, corresponding to 10-second
interstimuli intervals. Two minutes after the last
scotopic flash, in the same scotopic conditions, the
combined rod-cone response was elicited with a unique
Imax white flash.
Fig 1. Course of progressive retinal reattachment after subretinal administration of vehicle or lentiviral vector
preparation. In 3 representative eyes receiving the vehicle (TSSM, A), the LV-RPE65 lentiviral vector at dose 1
(B) or dose 2 (C), the upper panel shows infrared reflectance images immediately (left) and 7 days (right) after
injection. Serial optical coherence tomography of the macula (green arrows) performed immediately and at
days 2, 4, and 7 after administration show a progressive retinal reattachement. From the vehicle-injected eye to
dose 1– and dose 2–injected eyes, there was an increasing reattachement delay and an increasing degree of early
outer retinal alterations. LE, left eye; RE, right eye.
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particles. Shedding of lentiviral particles in body fluids
(urine, blood, and tears) after injection was evaluated
after RNA extraction of each fluid sample (NucleoSpin
RNAVirus Kit, Macherey-Nagel, D€uren, Germany) and
storage at 280C. Lentiviral particles were quantified
by quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR) targeting specific sequences of
the lentiviral genome. Briefly, for each sample, 400 ng
RNA were subjected to DNase digestion and reverse
transcribed using SuperScript VILO cDNA synthesis
kit (Life Technologies, Carlsbad, Calif) according to
the manufacturer’s instructions. The targeted
transgene sequence was then amplified using iTaq
universel SYBR Green Supermix on a CFX384 wells
thermocycler (Biorad, Marnes-la-Coquette, France)
with the following primers: forward primer,
50-ATCCCTGTCACCTTTCATGG-3’; reverse primer,50-TGGGAATAAATGGCGGTAAG-30 designed with
Primer3 version 2.3.7 (http://sourceforge.net/projects/
primer3). Samples and standard points were tested in
duplicate.
The possible integration of lentiviral genome was
assessed on genomic DNA extracted from flash frozen
organ biopsies using the DNeasy blood and tissue kit
(Qiagen, Hilden, Germany). DNA samples were stored
at 220C and processed for quantitative PCR targeting
the human RPE65 mRNA sequence using the primer
pair described above.
Ocular immunohistochemistry study. Enucleated eyes
were fixed in 4% paraformaldehyde immediately af-
ter scheduled death procedures for 1 hour, then pre-
served in 1% paraformaldehyde, until they were
equilibrated overnight in sucrose 30% and embedded
in albumin from hen egg white (Fluka, Buchs,
Switzerland). Sixteen-mm cryosections were obtained
Fig 2. Assessment of ocular and retinal inflammation after LV-RPE65 subretinal injection. In (A) to (C) is dis-
played the Fundus blue reflectance imaging from the left eye of animal 1A, 2 days after the subretinal delivery
of dose 1 LV-RPE65. (A) shows an early vasculitis-like perivenular reaction with progressive fading by day 7
(B) and resolution by day 14 (C). Fluorescein angiography in (D) performed at day 4 after administration did
not reveal any active vasculitis. Anterior chamber cell count (E) showed a transient mild inflammation in
TSSM- and dose 1–injected eyes and a more intense reaction in dose 2–injected eyes that resolved progressively
over the course of follow-up. Similarly, vitreous cell count (F) showed a transient mild inflammation in TSSM- and
dose 1–injected eyes and a moderately intense inflammation in dose 2–injected eyes that also resolved progres-
sively over the course of follow-up. LE, left eye; RE, right eye.
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Immunohistochemistry was performed on macular
and extramacular sections containing the injected
area with antibodies directed against CD45
(#M0701, Dako, Zug, Switzerland), glial fibrillary
acid protein (GFAP, #G3893, Sigma, Buchs,
Switzerland), vimentin (#MA5-11883, Thermofischer
Rockford, Ill), Iba-1 (#019–19741, Wako, Neuss,
Germany), and M-Opsin (#AB5405, Chemicon,
Temecula, Calif) which were revealed with the
appropriate secondary antibodies coupled withAlexa Fluor488 (Molecular Probes, Eugene, Ore).
Cryosections were also processed for hematoxylin-
eosin stain.
Organhistology. Organ biopsies from inferior eyelids,
right/left optic nerves, right/left geniculate bodies,
right/left visual cortex, heart, liver, right/left lung,
right/left ovary, right/left kidney, and right/left mandib-
ular lymph nodes were obtained after sacrifice and
transferred into formalin. After conventional tissue
processing, evaluation for macroscopic/microscopic
morphologic alterations and signs of inflammation
Fig 3. Multimodal imaging following subretinal administration of TSSM in 4 control Macaca fascicularis eyes.
Infrared reflectance (IR) performed immediately after subretinal injection (day 0) showed the topography of the
subretinal bleb, and revealed variable degrees of fundus pigmentary changes at day 28 after injection. Similarly,
short-wavelength autofluorescence (SW-AF) and blue reflectance (BR) showed retinal pigment epithelium changes
related to the detached retinal area or the injection site. Noticeably, the eye C (RE) exhibited a perifoveal concentric
circular pattern in the 3 modalities, and the eyes C (RE), 1B (RE), and 2B (RE) showed a concentric hyporeflective
and hypoautofluorescent ring at the periphery of the detached retinal area. LE, left eye; RE, right eye.
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masked to group assignment.
RESULTS
Subretinal administration of LV-RPE65 vector and
vehicle. A subretinal detachment of the macular areawas obtained in all the 8 injected eyes (TSSM: 4
eyes; LV-RPE65 dose 1: 2 eyes; and LV-RPE65 dose
2: 2 eyes). The mean detached surface was
119 6 4.2 mm2 among the 4 eyes injected with
LV-RPE65, showing good reproducibility for the
delivery process. In the left eye (LE) of animal 2B
Fig 4. Multimodal imaging following subretinal administration of LV-RPE65 in 4 control Macaca fascicularis
eyes. Infrared reflectance (IR) performed immediately after subretinal injection (day 0) showed the topography
of the subretinal bleb and revealed mild fundus pigmentary changes at day 28 after injection. Similarly, short-
wavelength autofluorescence (SW-AF) and blue reflectance (BR) showed moderate retinal pigment epithelium
changes related to the detached retinal area or the injection site. Particularly, the 2A (RE) eye showed a concentric
peripheral ring similar to those observed in TSSM-injected animals (Fig 3). The 2 B (LE) eye that received an
additional intravitreal dose of LV-RPE65 presented a macular hyperautofluorescence suggestive of more advanced
alterations of the outer retina and retinal pigment epithelium. By day 28, BR imaging showed no residual signs of
the early, vasculitis-like reaction displayed in Fig 2. LE, left eye; RE, right eye.
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retrohyaloidal injection with dispersion of the
lentiviral solution within the vitreous cavity, and
was followed by a second successful subretinalinjection resulting in a 121-mm2 bleb. OCT and
fundus infrared reflectance images showing
blebs immediately after injection are displayed in
Figs 1–3, respectively.
Fig 5. Optical coherence tomography of the fovea after subretinal administration of the LV-RPE65 lentiviral vector
or the vehicle (TSSM). Horizontal optical coherence tomography scans at baseline (before subretinal administra-
tion), day 28, and day 90 (when available) showed minimal, reversible outer retinal changes with ellipsoid zone
hyporeflectivity in one TSSM-injected eye (C [RE]). There was mild outer retinal alterations by day 28 in eyes
receiving dose1LV-RPE65 (1A [LE], 1B [RE]), forwhich no imagingwas available byday 90due to earlier sacrifice
in the study design. Similarly, there were moderate changes with a granular appearance of the ellipsoid zone in one
dose 2 LV-RPE65–injected eye (2A [LE]), with recovery of ellipsoid zone integrity by day 90, but there was more
pronounced outer retinal alterationswith the presence of an hyperreflectivematerial in the other LV-RPE65–injected
eye (2B [LE]), that also received an accidental intravitreal dose of lentiviral vector. LE, left eye; RE, right eye.
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observed in 2 LV-RPE65–injected NHPs at the 30-day
time point (animal 1A: 20.34 kg, animal 2A:
20.52 kg) that had resolved by 90 days for the animal
that reached this time point (2A). Animal C who was
dosed subretinally with TSSM only also presented a
transitory weight loss (20.41 kg) at 30 days that had
resolved by 90 days. There were no unscheduled
deaths during the study period.
Clinical and imaging ocular observations. The evalua-
tion of subretinal blebs by serial OCTs during the first
postoperative week showed a progressive reattachment
that was completed at the fovea by day 4 in TSSM-
injected eyes, and by day 7, at the latest, in LV-RPE65
dose 1–injected eyes. LV-RPE65 dose 2–injected eyes
showed persistence of subretinal material at day 7, as
illustrated in Fig 1, B and C.
Two days after subretinal injection, biomicroscopy
revealed a moderate-to-intense anterior chamber
and vitreous cellular reaction, which slowly resolved
over the follow-up period. This reaction was
more intense in dose 2–injected eyes than in dose
1– and vehicle-injected eyes (Fig 2, E and F). Inparticular, the LE of animal 2B which had received
an extra intravitreal dose of LV-RPE65 presented
initially an intense anterior chamber reaction (41),
requiring an intravenous dose of methylpredniso-
lone, followed by progressive resolution of the intra-
ocular reaction.
Surprisingly, all 4 eyes receiving LV-RPE65
presented an early vasculitis-like reaction with perive-
nular whitening and blood extravasation, suggestive of
frost-branch angiitis. There was no sign suggestive
of retinal necrosis, and the retinal signs subsided
progressively over 14 days (Fig 2). This reaction
was best recorded on fundus blue reflectance, indi-
cating its localization to the inner retina around
middle-sized retinal venules. Fluorescein and indoc-
yanine green angiography performed at day 2
(animals 2A and 2B) or day 4 (animals 1A and 1B)
did not show signs of active vasculitis, pointing to
the early and transitory timing of this phenomenon.
There were variable fundus pigmentary changes in
TSSM- and LV-RPE65–injected eyes, as illustrated in
Figs 3 and 4. A circular hyperpigmentation was
frequently visible at the periphery of the detached
Fig 6. Changes in retinal layer thickness following subretinal admin-
istration of LV-RPE65 or the vehicle (TSSM). Retinal layer thick-
nesses were computed as the mean thickness within the detached
area, along one vertical and one horizontal axis through the fovea.
They are reported for 4 TSSM-injected control eyes (values pooled
as mean 6 SD, dark blue), and 4 LV-RPE65–injected eyes receiving
dose 1 (animals 1A left eye, and 1B right eye, pale blue) or dose 2 (an-
imals 2A left eye, and 2B left eye, mid-blue). (A) represents photore-
ceptor outer segment-retinal pigment epithelium thickness. An initial
thinning was observed in control eyes dosed with TSSM, and in eyes
receiving LV-RPE65 where it was more pronounced, with progressive
recovery of photoreceptor outer segment-retinal pigment epithelium
thickness over the follow-up. In the eye 2B (LE) that inadvertently
received an extra intravitreal high dose of LV-RPE65 during adminis-
tration procedure, a significant residual thinning persisted at day 90.
(B) Quantification of the outer nuclear layer thickness shows an initial
thinning effect and partial resolution in LV-RPE65–injected eyes eval-
uated at day 90. Control eyes receiving TSSM showed a milder outer
nuclear layer thinning, which remained stable until day 90. (C) Inner
retinal layers thickness, from the internal limiting membrane to the
interface of the inner nuclear/outer plexiform layers, did not show ma-
jor significant variation. Thickness of inner retinal layers was very
close to baseline values by days 28 and 90 in TSSM-injected and
LV-RPE65 injected eyes. LE, left eye; RE, right eye.
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injected and 1 LV-RPE65–injected eye, visible on
infrared and blue reflectance, and short-wavelength
autofluorescence. There was also hypo/hyperautofluor-escent changes related to the injection site, and a pattern
formed by multiple concentric rings variably observed
around the fovea.
A transient decrease in IOP was observed in all eyes
after surgery, and was more pronounced in
LV-RPE65–injected eyes than TSSM-injected eyes,
probably related to the degree of postoperative intraoc-
ular inflammation. However, it was self-resolving with
mean IOP measurements of 10-mm Hg, 8-mm Hg,
and 11-mm Hg at day 28 in eyes dosed with
LV-RPE65 dose 1, dose 2, and TSSM, respectively.
Assessment of retinal layers on OCT. The qualitative
evaluation of retinal layers at the macula with serial
OCT showed outer retinal changes at day 28 in
LV-RPE65–injected eyes (Fig 5). The ellipsoid zone
(EZ) demonstrated an irregular aspect in eyes 1A
(LE), 1B (right eye [RE]), and 2A (LE), while the
hyperreflective material observed after bleb formation
(Fig 1) persisted in the LE of animal 2B, impairing
the visualization of outer retinal layers at the macula.
The ONL also showed a relative thinning in eyes
dosed with LV-RPE65. At the 90-day time point, eye
2A (LE) showed a partial restoration of EZ, and eye
2B (LE) showed a partial regression of the dense
hyperreflective material, and persistence of outer
retinal layer alterations. EZ disruption and ONL
thinning were also observed, but to a milder degree, in
eyes dosed with TSSM (Fig 5 shows OCTs from
animal C [RE]). For all groups but not for all animals,
accumulation of subretinal hyperreflective material
was observed at the bleb edge (not shown).
A quantitative assessment of retinal layer thickness
changes on OCT scans positioned at the fovea in
detached retinal areas is displayed in Fig 6. It showed
in LV-RPE65–injected eyes a transient, partially revers-
ible POS-RPE layer thinning. The ONL thickness was
also moderately affected. To a lesser degree, outer
retinal layer thicknesses in control TSSM-injected
eyes were also altered by the subretinal detachment,
and demonstrated similar trends with reversible outer
segment thinning and a moderate, persistent ONL thin-
ning in the detached area. A similar assessment was
performed for the inner retinal layers (from the internal
limiting membrane to the outer plexiform/inner nuclear
layer interface), that showed no relevant thickness
changes in TSSM-injected and LV-RPE65–injected
eyes.
An analysis of retinal layer thickness change was also
conducted over an identical location close to the macula
in all eyes,38 allowing a better intereyes comparability
of the results in terms of relative change. This analysis
showed a reversible decline in ONL thickness and a
relative, partial decrease in POS/RPE thickness in all
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confirmed that the inner retinal layer thickness was not
modified after LV-RPE65 injection.
Electroretinography. To evaluate the effects of subreti-
nal administration of either LV-RPE65 or TSSM on
retinal activity, we compared full-field ERG
recordings performed 14, 28, and 90 days after
injection with baseline measures acquired before
treatment, in each animal (Table II). Baseline
responses showed evident interindividual quantitative
variations of the a- and b-wave amplitudes. For
example, min-max values ranged from 40 to 108 mV
for the b-wave amplitude of the rod response or from
22 to 49 mV for the a-wave amplitude of the cone
response. We thus decided to evaluate intraindividual
variations at the different time points. Of the 4 TSSM-
injected eyes, 3 eyes maintained equivalent retinal
activity (Fig 7B). In the fourth TSSM-injected eye C
(RE), we observed over 40% decrease in response
amplitudes to all illumination conditions after
injection as compared to baseline, but no differences
in peak times. Absent or minor modifications of ERG
responses were noticed for the 2 LV-RPE65–injected
eyes 1B (RE; dose 1) and 2A (LE; dose 2; Fig 7, C
and D and Table II), whereas the 1A (LE) dose 1
showed significantly reduced amplitudes at the latest
time point by 40% or more, but without peak time
increase. The fourth eye injected with LV-RPE65 dose
2 (2B [LE]) showed 90 days post-injection both
reduced amplitude and increase in peak time in
scotopic conditions, which could be the manifestation
of retinal cellular suffering (Table I). We were not
able to identify exclusive inner retinal dysfunction in
LV-RPE65– or TSSM-injected eye following ERG
analysis of a- and b-wave amplitudes and peak times.
Biodistribution and organ toxicology. To optimize
quantitative PCR sensitivity for detecting circulating
lentiviral particles or integrated lentiviral genomes, we
designed a primer pair targeting specifically the lentivi-
ral transgene cassette. The forward primer is located on
RPE65 cDNA and the reverse primer on theWoodchuck
hepatitis virus Posttranscriptional Regulatory Element
sequence added in the vector, thereby avoiding putative
amplification of the endogenous RPE65 macaque gene.
This primer pair allowed to detect unequivocally 10
copies of target matrix DNA in the reaction mixture
(Supplementary Fig 3).
Circulating particles. To evaluate the extraocular
shedding of lentiviral particles after subretinal delivery,
qRT-PCRwas performed on lachrymal fluid, serum, and
urine collected at regular intervals (days 2, 4, 7, 14, 30,
and 90). Based on the sensitivity of the qPCR and the
amount of RNA extracted from the different fluids, we
calculated a detection threshold of 250 particles/mlfor serum, 60 particles/ml for lachrymal fluid, and
10 particles/ml for urine. No viral particle was
detected in any body fluid regardless the time points
or the animal being studied all quantification cycles
(Cq) being equivalent or above negative control
(Supplementary Fig 3).
Integrated lentiviral sequences in genomic
DNA. Despite the very limited shedding of the vector,
we prospected for extraocular genomic integration of
the LV. Biopsies from inferior eyelids, right/left optic
nerves, right/left geniculate bodies, right/left visual
cortex, heart, liver, right/left lung, right/left ovary, right/
left kidney, and right/left mandibular lymph nodes were
collected at the end of the experiment and genomic
DNAwas extracted for quantitative PCR of the integrated
therapeutic cassette. The threshold sensitivity of our pro-
cedurewas10copies in50ngofgenomicDNA, the lowest
detected point of the standard curve being 10 copies. This
limit of detection was estimated to be at 0.83 106 copies/
organ for heart (containing around 4.93 1014 diploid ge-
nomes), 13 106 copies/organ for lung (containing around
6.8 3 1014 diploid genomes), 2 3 106 copies/organ for
kidney (containing around 15.83 1014 diploid genomes),
12 3 106 copies/organ for liver (containing around 76.5
3 1014 diploid genomes), and brain (containing around
75.8 3 1014 diploid genomes). We did not detect any
integration of the recombinant lentiviral genome in any
samples tested showing the systemic safety of lentiviral
administration into the subretinal space.
Organ histology. No macroscopic or microscopic
morphologic alterations nor signs of unexpected inflam-
mation could be detected in biopsies sampled from
inferior eyelid, optic nerve, geniculate bodies, visual
cortex, mandibular lymph node, heart, lung, liver,
kidney, and ovary tissues in animals sacrificed at day
28 (1A-B) or day 90 (2A-B) after LV-RPE65
subretinal administration nor in the animal sacrificed
90 days after receiving TSSM only (C).
Ocular histologyand immunohistochemistry. After sac-
rifice at day 28 for dose 1 LV-RPE65–injected animals
and at day 90 for dose 2 LV-RPE65–injected animals,
eyes were processed for histologic and immunohisto-
chemical analysis. Conventional hematoxylin-eosin
stain showed normal ocular structures in all eyes and
revealed a mild choroidal lymphocytic infiltrate in
animal 1A (RE; TSSM), and a similar finding
associated to focal outer blood-retinal barrier
breakdown and mild vitritis in animal 2B (LE; LV-
RPE65 dose 2). To evidence remnants of
inflammatory cell migration, a retinal section
containing the region of subretinal injection (bleb)
was labeled for the CD45 leukocyte marker. No
differences in CD45-positive labeling were observed
between noninjected, TSSM-injected, or LV-RPE65–
Table II. Retinal activity characterization using full field electroretinogram (ERG) recordings following subretinal injection
ID Eye Group Time
Photopic (cone responses) at i-max 0.4 log cds/m2
Scotopic (rod responses)
at 20.8 log cds/m2
Scotopic (mixed rod-cone responses)
at i-max 0.4 log cds/m2
a-wave b-wave
Ratio
b/a
Fl-wave b-wave a-wave b-wave
Ratio
b/a
Amp
(mV)
Peak
time (ms)
Amp
(mV)
Peak
time (ms)
Amp
(mV) Amp (mV)
Peak
time (ms) Amp (mV)
Peak
time (ms) Amp (mV)
Peak
time (ms)
C LE - Baseline 47 14 205 31 4.36 190 92 60 145 16 367 38 2.53
D15 34 14 137 30 4.03 123 54 62 100 17 243 39 2.43
D30 33 14 136 30 4.12 129 55 61 98 16 254 38 2.59
D90 22 14 134 29 6.09 128 61 61 105 17 285 38 2.71
1B LE - Baseline 29 14 126 27 4.34 105 51 56 104 16 251 36 2.41
D15 38 14 119 32 3.13 111 64 62 130 14 270 36 2.08
D30 30 13 127 30 4.23 140 57 59 132 14 298 34 2.26
C RE TSSM Baseline 49 14 213 30 4.35 186 93 60 147 16 382 38 2.60
D15 30 15 125* 30 4.17 94* 46* 64 97 17 214* 41 2.21
D30 22* 14 105* 30 4.77 96* 34* 60 79* 16 194* 39 2.46
D90 23* 15 107* 29 4.65 96* 42* 61 86* 17 224* 38 2.60
1A RE TSSM Baseline 32 14 153 29 4.78 109 54 60 119 17 287 40 2.41
D15 41 13 158 28 3.85 130 75 60 144 16 346 38 2.40
D30 22 15 122 29 5.55 69 44 58 109 17 240 41 2.20
2A RE TSSM Baseline 25 13 149 27 5.96 144 88 55 110 16 360 39 3.27
D15 35 14 150 29 4.29 120 84 57 107 16 332 39 3.10
D30 32 13 168 27 5.25 172 118 53 134 15 454 40 3.39
D133 29 13 137 27 4.72 131 79 53 97 15 299 40 3.08
2B RE TSSM Baseline 25 13 109 27 4.36 107 65 57 107 15 305 35 2.85
D15 38 12 116 32 3.05 148 64 60 138 13 320 35 2.32
D30 43 11 140 32 3.26 181 89 57 152 14 387 34 2.55
D133 29 13 112 28 3.86 101 60 61 104 16 266 38 2.56
1A LE Dose 1 Baseline 32 12 160 29 5.00 129 61 61 130 17 302 40 2.32
D15 28 14 112 28 4.00 166 53 62 102 16 230 39 2.25
D30 19* 15 91* 29 4.79 53* 27* 59 83 17 194 42 2.34
1B RE Dose 1 Baseline 22 14 97 27 4.41 84 40 56 91 16 212 35 2.33
D15 41 14 109 32 2.66 120 50 64 129 15 246 37 1.91
D30 39 13 110 31 2.82 140 50 59 138 15 288 35 2.09
2A LE Dose 2 Baseline 27 13 163 27 6.04 163 108 54 113 15 400 40 3.54
D22 22 13 111 28 5.05 105 73 55 91 16 305 40 3.35
D30 20 14 120 28 6.00 105 82 57 93 16 293 42 3.15
D90 16* 14 96* 28 6.00 93* 71 54 88 16 294 41 3.34
2B LE Dose 2 Baseline 36 13 139 27 3.86 151 83 57 129 15 365 35 2.83
D22 29 13 140 29 4.83 97 67 64 115 17 286 41 2.49
D30 38 14 123 32 3.24 120 54† 62† 131 16 318 38 2.43
D90 19* 14 93 29 4.89 68* 51† 63† 79† 17† 213† 40† 2.70
*. 40% decrease compare to baseline.
†decrease of amplitude coupled to mild increase of peak time.
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Fig 7. Retinal activity evaluation 30 days after subretinal injection. ERG tracings obtained at baseline and 30 days
after injection in photopic and scotopic conditions. In photopic conditions, the Imax flash responsewas obtained by
15 stimuli delivered at 1.3 Hz against a 25 cd/m2 background (first column). The oscillatory potentials were ex-
tracted from the Imax photopic response (second column). A final 30-Hz flicker at Imax stimuli was recorded (third
column). After 20 minutes of dark adaptation, scotopic responses to 0.4 cd.s/m2 stimuli (average of 5 flashes) were
recorded in dark (fourth column). Finally, in similar scotopic conditions, a unique flash at Imax intensity was
applied to record the mixed rod-cone response (fifth column). The displayed tracings were obtained in (A) an un-
injected eye (1B [LE]), (B) a TSSM- injected eye (2A [RE]), (C) a dose 1 LV-injected eye (1B [RE]), and (D) a
dose 2 LV-injected eye (2A [LE]). All eyes maintained photopic and scotopic retinal activity 30 days after injec-
tion. LE, left eye; RE, right eye.
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Vimentin glial markers labeling M€uller cells and
astrocytes did not show any difference between these
eyes (Supplementary Fig 4). Finally, the microglia
Iba-1 staining did not either demonstrate differences
in microglial activation or migration between these
groups 30 or 90 after injection (Supplementary Fig 4).DISCUSSION
In this preclinical study, we assessed the ocular and
systemic safety after subretinal administration of an
LV for RPE65 gene replacement in healthy NHPs.
Considering that no systemic or periocular anti-
inflammatory agents were preventively administered
to the subretinally injected animals, subretinal injection
of an LV was well tolerated in low-dose injected
animals, but not in the high-dose injected animals who
developed a strong retinal and ocular inflammatoryreaction, that did not persist but induced seemingly irre-
versible structural alterations. This observation suggests
that the alterations observed at the fovea level could be
markedly reduced if the injection procedure and the
retina environment are well controlled. This moderate
tolerance has to be compared with previous preclinical
and clinical studies with AAV vectors, in which large
animals or patients all received periocular16,28,43 or
systemic18,33 anti-inflammatory therapy. An exception
was made for animal 2B which endured an accidental
intravitreous extra-injection and developed a marked,
but transient intraocular inflammation and who received
an intravenous anti-inflammatory treatment. This
animal developed a mild transient weight loss, but this
phenomenon was also observed in one TSSM-injected
animal and might be caused by repetitive anesthesia
imposed by the study design. Remarkably, no vector
shedding or inaccurate extraocular targeting was
demonstrated, showing the safe restriction of the vector
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reports suggesting a high systemic safety of nonhuman
LVs administered subretinally.44-47
In the present study, in contrast with previous reports
that did not focus on early events, animals were
followed at short intervals with multimodal imaging to
assess invivo theacute effects of subretinalLVadministra-
tion on retinal structures. Interestingly, the kinetics of sub-
retinal bleb detachment showed prolonged reattachment
times (by 3–4 days) for LV-RPE65–injected eyes as
compared with vehicle-injected eyes. This phenomenon
may be caused by a transient impairment of the RPE
pumping capacity during an acute phase corresponding
to thevector entry and integration intoRPEcells, the latter
process starting within 4 hours and reaching a plateau at
24–48 hours.48 Alternatively, the transient presence of
viral particles in the subretinal fluid could provoke an
osmolality imbalance that maintains the detachment
of the neurosensory retina from the RPE longer than in
control-injected eyes.Whether this prolongeddetachment
results fromthe alterationofRPEcell functions in reaction
to vector entry, from an inflammatory process, or from
an osmolality effect remains to be determined.
Noticeably, we observed an early perivascular reac-
tion, evidenced at day 2 and self-resolving within
14 days, consisting perivenular whitening at the level
of retinal venules within the detached area. There was
no angiographic vasculitis at day 2, suggesting that
severe blood-retinal barrier rupture did not occur or
occurred before this time point. Although a similar
reaction has not been reported by other groups, we
did not find previous reports of fundus examination
or blue-reflectance imaging, which best evidenced
the phenomenon, as early as day 2 after subretinal
delivery of viral vectors. To investigate its cause, we
searched for several inflammatory and glial markers
by immunohistochemistry but did not find overexpres-
sion of CD45 (lymphocytes), Iba-1 (microglia), GFAP
or vimentin (astrocytes and M€uller cells) in
LV-RPE65–injected as compared with vehicle-
injected eyes. This may result in part from the delayed
ex vivo evaluation at 1 and 3 months after administra-
tion. Nonetheless, these histologic data assess that this
transient reaction did not provoke a chronic modifica-
tion of the glial cells often observed after retinal
injuries.49,50
Importantly, the in vivo evaluation of retinal layer
thickness by serial OCT scans did not show any signif-
icant thinning of inner retinal layers, where the perivas-
cular reaction was detected.
While the perivascular phenomenon occurred in all
eyes receiving LV-RPE65, no significant ERG alter-
ations were observed in all the 4 animals, indicating
limited consequences on retinal function. Similarly,ERG alterations observed in LV-RPE65–injected eyes
did not preferentially involve b-wave responses,
suggesting that the immediate post-injection vascu-
litis-like process did not result in specific inner retinal
cellular defects detectable by this analysis. Moreover,
no isolated b-wave modifications were observed,
suggesting they were rather caused by a-wave changes
originating from outer retinal variations rather than
from inner retinal damages.
Outer retinal alterations were also manifested on
multimodal imaging as hyper/hypopigmentation, and hy-
per/hypoautofluorescencemostly at the borders of the de-
tached areas. OCT also showed a partially reversible
thinning of outer retinal layers. Similarly to ERG
a-wave variations, these changes were more frequent
and more severe in LV-RPE65–injected eyes, but were
also observed to a variable and milder degree in
vehicle-injected eyes. Despite the limited number of
injected eyes (4 with TSSM, 2 with low-dose LV-RPE65,
and 2 with high-dose LV-RPE65), these observations
emphasize the limits of the subretinal route with current
injection methods and devices that do not prevent retinal
suffering, particularly at the POS/RPE interface, and
that lack reproducibility. The crescent-shaped pigmen-
tary and autofluorescent modifications visible on Figs 3
and 4 variably affected both vehicle- and lentivirus-
injected eyes. This imaging pattern points to a biological
effect of the retinal detachment rather than to an infec-
tious manifestation. Moreover, although restoring a
retinal function in the macular area should bring major
benefits to the patients, this area appears to be especially
vulnerable to the damaging effects of acute detachment,
as was already highlighted in one clinical study evalu-
ating AAV-based RPE65 gene therapy.26 In the present
study, 3 out of 4 animals presented at 1 or 3 months a par-
tial improvement of early macular changes visible on
OCT after LV-RPE65 administration. In contrast, animal
2B which received an extra intravitreal dose followed by
an intense intraocular inflammation presented a subfo-
veal hyperreflective deposit that had not resolved at the
3-month time point, showing the higher susceptibility
of the fovea for focal damage in case of an adverse event.
Among patients included in AAV-RPE65 gene therapy
clinical trials, structural damage of the fovea has been
reported, such as macular hole formation17 and foveal
thinning,22,23,26 To prevent these drawbacks, alternate
strategies have been advanced, such as minimizing
hydrodynamic stress during injection51,52 or performing
multiple perimacular detachments.26
Animal models of retinal detachment have shown that
detachment of the neurosensory retina from the RPE
leads to a glial reaction mediated by M€uller cells53,54
and microglia,55 and to photoreceptor damage with outer
segment shortening.56 Photoreceptor damage results from
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tive complement57 and RhoA pathways.58 Interestingly,
there is a decrease in glial markers overexpression59
and progressive restoration of POSs56 after lengthy
periods of reattachment (5 months), which is consistent
with our findings. Recently, imaging studies using OCT
segmentation on patients with rhegmatogenous retinal
detachment also showed a re-increase in POS volume
after retinal reattachment.60 In LV-RPE65–injected eyes,
damages related to the induced retinal detachment may
be potentiated by the inflammation reaction to the viral
vector, explaining the less-pronounced photoreceptor
restoration as compared with control eyes. However,
multimodal imaging findings in the present study showed
a variability in retinal alterations after subretinal adminis-
tration of TSSM or the lentiviral solution, as reported in
patients who received subretinal gene therapy.22,26
Additional studies with increased number of vector-
injected eyes will be necessary to demonstrate in greater
detail the functional and structural effects of subfoveal
injections.
The blood-retinal barrier, by contributing to the intra-
ocular immune privilege, favors the systemic tolerance
of subretinally injected vectors. However, mechanical
alterations of the RPE induced by the detachment, and
the transient perivascular reaction observed in this study
may compromise the integrity of the outer and inner
blood-retinal barriers, respectively. Although the anal-
ysis of body fluids and organs did not indicate shedding
of viral particles, it may have elicited a subclinical,
low-grade immune reaction, which raises concerns
regarding possible vector reinjection.43,61 The
evaluation of the immune response against the
LV-RPE65 vector will be addressed in a future report.
Limitations of this study include the limited number
of NHPs due to ethical restrictions, and the fact that
one animal was treated after surgery with systemic
corticosteroids due to an intense intraocular inflamma-
tion. Additional experiments are needed to evaluate
the dose safety, to determine whether vitrectomy should
be performed systematically before subretinal injection,
whether the injection site should be located in a specific
area or sealed to reduce vitreal leakage of the vector, and
whether local or systemic corticosteroids should be
administered.
The current RPE65 clinical trials are proposing an
AAV-based gene transfer for gene replacement in RPE
cells. Despite positive effects in the first years following
vector administration, several long-term reports show
continuation of retinal degeneration, and loss of early
visual benefits several years after treatment22,23,62 One
hypothesis explaining this major drawback is the low
level of therapeutic gene expression obtained in thesetrials, which is incompatible with the level required in
the human retina.22 Thus, the development of alternate
gene transfer tools could open new therapeutic perspec-
tives.19 Given the previously established high efficiency
of LVs to target RPE cells,30,31,63,64 this vector may be a
potential candidate for inherited retinal disorders due to
RPE65 deficiency, but also for other RPE-specific
diseases such as Best vitelliformmacular dystrophy, pro-
vided that its local tolerance is improved. This improve-
ment may be achieved by the co-administration of a
systemic adjuvant anti-inflammatory prophylaxis and/
or optimization of the vector delivery. The study herein
further supports the limited systemic dispersion of LVs
following subretinal administration. It also demonstrates
that further optimization of the retinal tolerance to the
LV-RPE65 LV and to its subretinal delivery technique
are crucial to render the vector eligible for gene transfer
in the human retina.ACKNOWLEDGMENTS
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57.e1 Matet et al October 2017APPENDIXSupplementary Fig 1. Localization of the region of interest for segmentation of retinal layers over an identical
area within the detached retina in all injected eyes, using a custom algorithm. Heat map of the total retinal thick-
ness superimposed over the infrared reflectance image of the left eye of animal 1A, at day 30 after injection. The
green disc at the center of the circular grid represents the 1-mm diameter region of interest, located 1.1 mm su-
perior and 2.2mm nasal to the foveawith the axis between optic disc center and fovea used as horizontal reference.
A custom algorithm on the DiOCTA software was used to segment the retinal layers of this disc.
Supplementary Fig 2. Segmentation of retinal layers at the level of a
1-mm diameter circular region of interest localized within the de-
tached area of all subretinally injected eyes. The region of interest is
described in Supplementary Fig 1. (A) The thickness of the photore-
ceptor outer segments/retinal pigment epithelium showed a moderate
decrease in TSSM-injected eyes and a more pronounced decrease in
LV-RPE65–injected eyes. In one eye (2A [LE]), there was a late re-
increase of outer segment thickness. (B) The thickness of the outer nu-
clear layer was stable in TSSM-injected eyes, with an increase in vari-
ation at the 12-week time point and showed a moderate decrease in all
LV-RPE65–injected eyes, followed by a late return to baseline thick-
ness in eyes followed up until 12-weeks. (C) The thickness of inner
retinal layers from the inner limiting membrane to the outer limit of
the outer plexiform layer was globally stable after injection of
TSSM, LV-RPE65 dose 1, or dose 2. OS, outer segment; RPE, retinal
pigment epithelium; RE, right eye; LE, left eye.
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Supplementary Fig 3. Quantitative PCR standard curve and serum samples from macaque 2A. (A) Standard
curve was established with the shuttle plasmid containing the RPE65 recombinant lentiviral genome. Open circles
represent 10-fold serial dilutions of plasmidDNA ranging from 108 to 10 copies (duplicates). Crosses represent the
negative control without DNA showing the absence of amplification (triplicate). Linear regression: r25 0.999. (B)
The same standard curve as in A (open circles, duplicates) and serum samples of macaque 2A (each cross repre-
sents one sample in duplicate, n5 6 postinjection samples1 1 baseline sample) were processed in the same exper-
iment. For all the samples tested (n5 91), either amplification did not reach the detection threshold or the Cq value
did not fall below 35.
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Supplementary Fig 4. Long-term evaluation of retinal reattachment using immunohistochemistry. (A–D) GFAP la-
beling (green) of the region of retinal detachment (detached) after injection of TSSM (A, animal C-RE), LV-RPE65
dose 1 (B, animal 1A-LE), or LV-RPE65 dose 2 (D, animal 2B-LE) is not different from labeling of retinal region not
targeted by injection (undetached; C, animal 2B-LE). (E–H) Iba-1 labeling (green) of microglial cells is also similar
between detached retina after injection of TSSM (F, animal C-RE) or after injection of LV-RPE65 dose 2 (H, animal
2A-LE) and undetached region of the same eye (respectively, E and G). (I–K) CD45 labeling (green) of leukocytes
(arrowheads) revealed few leukocytes localized close to the RPE layer in both TSSM (I, animal 1A-RE) or
LV-RPE65–injected eyes (J, animal 1B-RE, K, 1A-LE). A–D, I –K: DAPI counterstaining in blue; A–H: upper
vertical white bars localize the inner nuclear layer and lower vertical white bars localize the outer nuclear layer;
RPE, retinal pigment epithelium; GFAP, glial fibrillary acid protein.
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